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ABSTRACT
Objective: The objective of the study was to compare the clinical and economic effectiveness of four combination antihypertensives recommended 
for Nigerians.
Methods: An open, randomized, controlled, and longitudinal double-blind trial of four groups of antihypertensives combinations: Telmisartan/
chlorthalidone/amlodipine (TCA), TC, CA, and TA was conducted among hypertensive patients. The participants were recruited from three hospitals 
in Enugu, and randomly assigned to the study groups. The primary outcome for this study was blood pressure (BP) control, based on Joint National 
Committee-8 and cost per BP control. The secondary outcomes were cost per quality adjusted life years (QALY) and patients’ self-reported health 
status. Descriptive and inferential statistics were used for statistical analysis.
Results: Of the 110 patients enrolled in the study, more than half were women (55.5%). The mean age of patients was 54.93±12.38. The enrollees 
had hypertension for over 9 years (9.17±8.40). About 77% of the patients completed the study in all the groups except for TA (66.7%). There was 
no difference in BP in all the groups at baseline and at end-of-study (p>0.050). However, the probability of BP control was highest in TCA group 
(0.37±0.01), followed by TC group (0.23±0.02). The TA group showed the most favorable cost per QALY, then CA, TC, and TCA in that order. The group 
with the most favorable cost per BP control was TCA (70.92±0.04), then TA (94.16±0.05).
Conclusion: The triple combination therapy of TCA had the best cost per BP control in the management of hypertensive patients. It demonstrated the 
highest probability of BP control.
Keywords: Antihypertensive medications, Combination therapy, Cost-effectiveness, Health status.
INTRODUCTION
Hypertension is still a global public health problem, and the financial 
cost associated with the disease continues to increase. It is estimated 
to affect over 1 billion people worldwide [1]. Sub-Saharan Africa (SSA) 
including Nigeria, account for approximately two-thirds of the global 
burden of hypertension. Hypertension is a major risk factor for the 
development of other cardiovascular diseases such as heart failure, 
stroke, and ischemic heart disease [2]. It is one of the leading causes 
of morbidity and mortality due to cardiovascular complications [3,4].
Nigeria presently has a population estimate of over 180 million, and thus 
the most populous country in Africa. In 2014, hypertension prevalence 
in Nigeria was estimated at 28.9% by the World Health Organization. 
However, in 2030, it is projected that the country will record 39.1 
million cases of hypertension among its adult population, with a 
prevalence of 30.8% [5,6]. Therefore, Nigeria contributes significantly 
to the hypertension burden in SSA. The high prevalence of hypertension 
in Nigeria is probably the result of increasing aging population, rapid 
urbanization, high intake of processed food, tobacco, and alcoholic 
products [7]. In addition, treatment and control of hypertension are low 
in Nigeria and other countries in SSA. For instance, a study reported 
that only 25.4% of patients attending a hypertension clinic in a tertiary 
hospital achieved desired blood pressure (BP) control [8].
Research has demonstrated that it is usually difficult achieving BP 
control with a single antihypertensive medication [9,10]. Evidently, 
about 75% of patients with hypertension would require two or more 
antihypertensive drug combination to ensure optimal BP control. This 
is because the specific cause of hypertension is rarely known and BP 
elevation is usually the product of multiple factors [9-11]. This makes 
it almost impossible to control BP with administration of a single 
antihypertensive medication.
Nevertheless, the Joint National Committee (JNC) on the prevention, 
detection, evaluation, and treatment of high BP (JNC-8), recommends 
monotherapy for initial treatment of hypertension in persons <60 years 
with BP above 140/90 mmHg, with or without diabetes, or chronic 
kidney disease (CKD). The BP target for patients aged 60 years and 
above was fixed at 150/90 mmHg. According to the guideline, failure 
to attain BP target with a single agent warrants the addition of one or 
more antihypertensive drugs with different mechanisms of action, after 
titrating initial therapy to a maximum dose, if necessary [12].
In general, hypertension is incurable. Hence, its treatment is lifelong. 
There are several available antihypertensive drugs for optimal BP 
control, with varying clinical effectiveness, cost implication, and side 
effect profile [13,14]. Some of the antihypertensive medications have 
proven efficacy, but are not affordable by majority of the populace.
However, there appears to be limited data comparing the efficacy 
and cost of antihypertensive combination therapies to determine the 
most suitable for black patients in Nigeria and sub-Sahara Africa in 
general. Therefore, this study aimed to compare the BP control and 
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cost-effectiveness of four different combinations of antihypertensive 
therapies recommended for black Africans [12,15,16].
METHODS
Study design
An open, randomized, controlled, longitudinal double-blind, and four-
arm parallel prospective trial with 6 weeks patient follow-up. The four 
arms of the study were: (1) Amlodipine + Telmisartan (AT), (2) A + 
Chlorthalidone (TAC), (3) T + C, and (4) A + T + C.
Study setting
This study was conducted in three private hospitals in Enugu. The 
facilities used were the Redemption Clinic, Kenyatta Hospital, and 
Doctor-on-call Clinic.
Study population
The study participants consist of 110 hypertensive patients who are 
18 years and above. The participants were recruited from the outpatient 
clinics of the study centers.
Patients’ allocation
The patients were allocated to the four arms of the study through a 
mixture of cluster and random sampling techniques. The patients 
in each clinic who met the inclusion criteria were distributed into 
clusters based on their matching characteristics. Subsequently, they 
were allocated to any of the four study arms through simple random 
technique. The criteria for grouping patients into clusters were age 
(18–59 years, ≥60 years), sex (male, female), and severity/comorbidity 
(CKD and/or diabetes, no CKD nor diabetes). Thus, giving rise to eight 
independent clusters.
Eligibility criteria
The study participants were recruited based on the following inclusion 
criteria: (1) Patients who are 18 years and above, (2) patients with 
compelling indications to use a combination therapy, and (3) patients 
who accepted to visit the clinic weekly for BP measurement and 
medication refill. The study excluded pregnant women.
Study instruments
The patients’ socio-demographic and clinical characteristics were 
obtained using a pro forma designed for such purpose. The socio-
demographic data retrieved include patients’ study group, age, sex, 
marital status, place of residence, occupation, monthly income, and 
educational level. The clinical variables were duration of hypertension 
since diagnosis, smoking and alcohol status, physical activity, use of 
herbal/traditional medicines, and adjuvant medications. Others are BP 
weekly readings, urine tests (e.g., urine protein, glucose, ketone, PH, 
nitrite, creatinine clearance, HC03, and Tca2+), blood tests (e.g., packed 
cell volume, bilirubin, glucose, fasting blood sugar, creatinine, low-
density lipoprotein, high-density lipoprotein, and triglycerides), and 
anthropometrics (e.g., height, weight, and hip circumference).
Data collection
The patients were assigned to four study groups. Each patient received 
a 6 weeks supply of antihypertensive drug combinations based on 
their group. Neither the physician nor the patients knew whether they 
received a triple combination antihypertensive or any of the three dual 
combinations. The patients were encouraged to take the medications 
daily and to monitor their BP. They were asked not to use any other 
antihypertensive medications throughout the study period of 6 weeks, 
and to report to the physician if there was a need to stop therapy. 
The patients were required to visit the clinic once a week, where the 
physicians examined their health status, measured, and recorded their 
BP and other clinical information.
The EQ-5D-5L English language version was used to measure patients’ 
health status. The instrument was developed and validated by the 
EuroQol group. It is internationally accepted and recommended for use 
in economic evaluation studies. The previous studies have re-validated 
the instrument among Nigerian population [17]. The EQ-5D instrument 
consists of the descriptive system and the EQ visual analogue scale (EQ-
VAS). The descriptive system had five dimensions: Mobility, usual care, 
self-care, anxiety/depression, and pain/discomfort. Each dimension 
had five levels: “(1) No problem, (2) slight problem, (3) moderate 
problem, (4) severe problem, and (5) extreme problem.” On the other 
hand, the EQ-VAS is a 20 cm scale with endpoints ranging from 0 to 100. 
The endpoints “0” and “100” signify “the worst health you can imagine” 
and “the best health you can imagine,” respectively. A box for recording 
patients’ self-rated health state was provided beside the scale.
Outcome measures
The primary outcome for this study was BP control based on JNC-8 
guideline and cost per BP control, while the secondary outcomes were 
cost per quality adjusted life years (QALY) and patients’ self-reported 
health status.
Statistical analysis
The patients’ socio-demographic, clinical characteristics, and health 
status were presented using descriptive statistics (frequency, 
percent, mean, and standard deviation). Student t-test was employed 
in examining the mean difference between the pre- and post-tests 
continuous laboratory values assessed across various study groups. 
One-way ANOVA test was used to determine the mean difference 
in systolic BP and diastolic BP for the different study groups. QALY 
was calculated using the average utility valuation score for the study 
population. *p<0.05 was considered to be statistically significant.
Ethical considerations
Ethical Committee of University of Nigeria Teaching approved the 
protocol of study. The patients who are willing to participate were 
provided with additional written information and asked to sign the 
study consent form or thumb print for illiterate patients.
RESULTS
Table 1 shows the socio-demographic and clinical characteristics of the 
patients. Out of the 110 patients enrolled in the study, more than half 
were women (55.5%). The mean age of patients was 54.93±12.38. The 
majority of the patients were married (78.2%) and are urban dwellers 
(82.7%). Less than half of the participants had tertiary education 
(44.5%). On average, the enrollees have had hypertension for over 
9 years (9.17±8.40).
Table 2 reveals the distribution of patients with controlled BP 
across the different study groups. At the end of study, patients on CA 
antihypertensive combination had the highest proportion of patients 
with BP control (83.3%), while enrollees on TA had the least BP control 
(54.2%).
Table 3 shows the probability of BP control and cost-effectiveness of 
a triple antihypertensive combination and three dual combinations. 
The results showed that patients’ reported health status indices (EQ-
VAS and EQ-5D index scores) were highest for CA group, followed by 
TCA group. The probability of BP control was highest in TCA group 
(0.37±0.001), while the least was the TA group (0.19±0.001). The TA 
group demonstrated the best cost per QALY, followed by CA, TC, and 
TCA in that order. However, the group with the most favorable cost per 
BP control was TCA (70.92 ± 0.04), followed by TA (94.16±0.05).
Figs. 1 and 2 shows the acceptability curves for the different 
interventions. TCA and TA had the best probabilities of being cost-
effective at competitive willingness to pay values.
DISCUSSION
This study was the first that compared the effectiveness of combined 
antihypertensive medications in terms of the BP control and QALY 
among patients in Nigeria and SSA. Its major findings demonstrate that 
the probability of BP control was highest among patients on the triple 
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combination (TCA) therapy, followed sequentially by patients on TC, 
CA, and TA. It also showed that TCA had the most favorable cost per 
BP control followed by TA. Other findings showed that patients on TA 
combination had the best cost per QALY.
Acceptability curves were used to present the result of cost-
effectiveness analysis. Acceptability curves illustrate the probability 
that any particular intervention is cost-effective conditional on the 
willingness to pay per QALY [18]. The curve also illustrates the degree 
of uncertainty in the estimates. The cost-effectiveness acceptability 
curve based on BP control showed that at willingness to pay above $40, 
TCA was the most cost-effective. At higher willingness to pay values, no 
other combination was a contender for cost-effectiveness with TCA. At 
willingness to pay below $40, TA was the most cost-effective.
The cost-effectiveness acceptability curve based of QALY showed that 
at willingness to pay below $600, TA was the most cost-effective. At 
willingness to pay above $600, CA and TCA were the most effective. 
Even at willingness to pay value above $2000, CA and TCA were most 
cost-effective. Although this values are high, they are still within the 
WHO threshold limit for cost-effectiveness [19,20].
The findings of this study were similar to those reported in a Greek study 
of the cost-effectiveness analysis of a triple combination of valsartan, A, 
and hydrochlorothiazide over its dual combinations [21]. In the study, 
Stafylas et al. found that the single triple combination therapy was 
more cost-effective compared to the dual combinations (valsartan and 
A, A and hydrochlorothiazide, and valsartan and hydrochlorothiazide). 
Even though the triple combination therapy was the most expensive, 
it is a cost-effective choice for patients with moderate to severe 
hypertension [21].
Table 2: Blood pressures control across the different study groups




16 (38.1) 26 (61.9)
Telmisartan+Chlorthalidone 10 (38.5) 16 (61.5)
Chlorthalidone+Amlodipine 3 (16.7) 15 (83.3)
Telmisartan+Amlodipine 11 (45.8) 13 (54.2)
Table 1: Socio-demographic and clinical characteristics of the patients
Variable Frequency (percent)
TCA TC CA TA Total
Age (years) 54.12±12.15 57.80±10.78 53.67±14.75 54.29±12.77 54.93±25.39*
Sex
Male 19 (45.2) 13 (50.0) 6 (33.3) 11 (45.8) 49 (44.5)
Female 23 (54.8) 13 (50.0) 12 (66.7) 13 (54.2) 61 (55.5)
Marital status
Single 4 (9.5) 2 (7.7) 1 (5.6) 0 (0.0) 7 (6.4)
Married 32 (76.2) 20 (76.9) 15 (83.3) 19 (79.2) 86 (78.2)
Widowed 5 (11.9) 4 (15.4) 2 (11.1) 5 (20.8) 16 (14.5)
Place of residence
Urban 33 (78.6) 22 (84.6) 16 (88.9) 20 (83.3) 91 (82.7)
Rural 5 (11.9) 2 (7.7) 2 (11.1) 2 (8.3) 11 (10.0)
Occupation
Unemployed 6 (14.3) 6 (23.1) 6 (33.3) 4 (16.7) 22 (20.0)
Employed 22 (52.4) 13 (50.0) 7 (38.9) 9 (37.5) 51 (46.4)
Retired 11 (26.2) 7 (26.9) 5 (27.8) 7 (29.2) 30 (27.3)
Student 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9)
Educational level
None 3 (7.1) 1 (3.8) 1 (5.6) 2 (8.3) 7 (6.4)
Primary 10 (23.8) 7 (26.9) 3 (16.7) 8 (33.3) 28 (25.5)
Secondary 12 (28.6) 3 (11.5) 3 (16.7) 5 (20.8) 23 (20.9)
Tertiary 16 (38.1) 14 (53.8) 11 (61.1) 8 (33.3) 49 (44.5)
Monthly income (naira) 47933±69733 75318±12697 27125±24879 35053±34858 49190±34858*
Duration of diagnosis 10.27±9.303 9.56±8.917 9.35±8.403 6.96±6.175 9.17±16.577*
Comorbidity
Diabetes 0 (0.0) 4 (15.4) 2 (11.1) 2 (8.3) 8 (7.3)
Hyperlipidemia 4 (9.5) 1 (3.8) 1 (5.6) 1 (4.2) 2 (1.8)
Stroke 1 (2.4) 1 (3.8) 2 (11.1) 1 (4.2) 8 (7.3)
Others 5 (11.9) 1 (3.8) 1 (5.6) 2 (8.3) 9 (8.2)
Smoking status
No 40 (95.2) 25 (96.2) 16 (88.9) 22 (91.7) 103 (93.6)
Yes 2 (4.8) 0 (0.0) 0 (0.0) 1 (4.2) 3 (2.7)
Alcohol status
No 28 (66.7) 14 (53.8) 11 (61.1) 14 (58.3) 67 (60.9)
Yes 14 (33.3) 12 (46.2) 7 (38.9) 9 (37.5) 42 (38.2)
Herbal/traditional medicine status
No 33 (78.6) 21 (80.8) 12 (66.7) 19 (79.2) 85 (77.3)
Yes 9 (21.4) 5 (19.2) 6 (33.3) 4 (16.7) 24 (21.8)
BP apparatus
No 28 (66.7) 16 (61.5) 12 (66.7) 16 (66.7) 72 (65.5)
Yes 14 (33.3) 10 (38.5) 6 (33.3) 7 (29.2) 37 (33.6)
Physical activity 
No 10 (23.8) 5 (19.2) 5 (27.8) 9 (37.5) 29 (26.4)
Yes 31 (73.8) 20 (76.9) 13 (72.2) 13 (54.2) 77 (70.0)
*Mean±standard deviation. TCA: Telmisartan/chlorthalidone/amlodipine, TC: Telmisartan/chlorthalidone, CA: Chlorthalidone/amlodipine, TA: Telmisartan/amlodipine. 
TCA: Telmisartan/chlorthalidone/amlodipine, TC: Telmisartan/chlorthalidone, CA: Chlorthalidone/amlodipine, TA: Telmisartan/amlodipine, BP: Blood pressure
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Although diuretics generally appear to be the least expensive 
antihypertensive drug class, they are usually recommended as 
monotherapy for hypertensive patients without any compelling 
indication. Nevertheless, studies have shown that hypertensive 
patients require an average of three drugs for effective BP control [9]. 
The present study lends support to this notion. It has been suggested 
that in black patients who require more than one drug for BP control, 
a combination of renin-angiotensin-aldosterone system inhibitor, 
dihydropyridine-type calcium channel blocker, and diuretic should be 
recommended.
In this study, the triple combination was the most cost-effective in 
terms of BP control. The probability of achieving target BP control was 
about 2 times higher for patients on triple combination compared to 
those taking dual combinations. Nevertheless, T and A combinations 
should be reserved as an alternative considering that patients 
benefitted more from the combination in terms of cost per QALY 
gained. Hence, in cases where the quality of life of the patient is of 
paramount importance, T, and A combination should be considered 
as the first option. Furthermore, patients who are unable to afford 
the triple combination therapy can equally benefit from the TA dual 
combination as it is the least expensive.
Furthermore, the current treatment guidelines advocate for the use 
of single fixed dose combinations for patients requiring more than 
one antihypertensive drug to attain optimal BP control [10]. This is 
because of the high prevalence of poor medication adherence often 
seen among patients on multiple medications. The use of fixed dose 
combinations improves medication adherence with resultant better 
BP control and reduction in cardiovascular risks associated with 
hypertension [14,22].
In addition, inappropriate antihypertensive combination or poor 
drug selection is thought to be responsible for low BP control in many 
countries. A large proportion of patients present to the hospitals or 
clinics with resistant hypertension, thus giving a unique challenge to 
the clinician regarding the best drug combination to prescribe bearing 
in mind patient’s characteristics and financial strength. Thus, there is 
need for fixed dose combinations.
The parameters of the laboratory tests (pre and post) carried out 
showed that the drug combinations had no significant effect on the 
electrolytes and other key parameters.
The findings of the present study would serve as possible guide for 
clinical practitioners in Nigeria; regarding the clinical and economic 
efficacies of commonly recommended antihypertensive drug 
combinations for the Black population.
Limitations
One major limitation of this study was that we used a small sample size 
from three settings in one town. Using a larger population and more 
centers are recommended in future studies.
Furthermore, extra laboratory tests would have given us a clearer 
effect of some pharmacodynamic properties of the different drug 
combinations, for example, liver function test and platelet count. 
There is growing evidence that thiazides and thiazide-like diuretic 
reduces platelet aggregation. However, the extent is still unknown and 
investigations are still ongoing [23,24]. Conducting platelet count test 
would have provided information about their effect on platelet count.
CONCLUSION
The triple combination therapy of TCA had the best cost per BP control 
followed by TA combination in the management of hypertensive 
patients. Furthermore, triple combination therapy demonstrated 
the highest probability of BP control. Therefore, this study provides 
valuable information to guide clinicians in decision-making regarding 
appropriate antihypertensive drug selection in the management of 
hypertensive patients. However, there is a need to further validate the 
study findings using larger population.
Table 3: Probability of BP control and cost-effectiveness of a triple antihypertensive therapy and 3 different dual combinations
Variables Study group (mean±standard deviation)
TCA TC CA TA
Cost of drugs per annum ($) 26.24±0.05 23.86±0.03 21.47±0.04 17.89±0.03
EQ-VAS score 71.60±14.09 65.47±20.53  71.30±11.10 66.22±11.05
EQ-5D index score (utility valuation) 0.78±0.10 0.74±0.12 0.80±0.13 0.69±0.11
Probability of BP control 0.37±0.01 0.23±0.02 0.21±0.01 0.19±0.01
QALY 0.128±0.0064 0.126±0.0073 0.130±0.0075 0.123±0.0058
Cost per QALY 205.00±8.69 189.37±9.35 165.15±7.14 145.45±7.1
Cost per BP control 70.92±0.04 103.74±0.06 102.24±0.03 94.16±0.05
TCA: Telmisartan+Chlorthalidone+Amlodipine; TC: Telmisartan+Chlorthalidone; CA: Chlorthalidone+Amlodipine, TA: Telmisartan+Amlodipine, BP: Blood pressure, 
QALY: Quality adjusted life years, EQ-VAS: EQ visual analogue scale
Fig. 1: Cost-effectiveness acceptability curve for the four 
interventions based on cost per blood pressure control
Fig 2: Cost-effectiveness acceptability curve for the four 
interventions based on cost per quality adjusted life years
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